I-Mab(Nasdaq: IMAB), a China-headquartered, clinical stage biopharmaceutical company, announced on Monday that it has added Andrew Zhu, MD, PhD to its Scientific Advisory Board.

Dr Zhu serves as a professor of Medicine at Harvard Medical School, director emeritus of Liver Cancer Research at Massachusetts General Hospital, chief scientific officer of Jiahui Health and director of Jiahui International Cancer Center in Shanghai. He has served on the Hepatobiliary Cancer Committee of the National Comprehensive Cancer Network, the Grants Selection Committee of the American Society of Clinical Oncology, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Cancer Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases and the Clinical Advisory Board of the Cholangiocarcinoma Foundation.

Dr Jingwu Zang, founder and chairman of I-Mab, said, 'We are delighted to welcome Dr Zhu to our scientific advisory board. His expertise in the field of gastrointestinal cancers, particularly hepatobiliary cancers, and his influence in the international medical and research communities, would be greatly beneficial to the development of our novel programs.'